[
  {
    "ts": "2025-12-23T01:09:58+00:00",
    "headline": "Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug",
    "summary": "The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-jumps-fda-oks-wegovy-pill-first-oral-glp-1-weight-loss-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8daff7dd-6122-3cb9-ad16-8a3df5fa8764",
      "content": {
        "id": "8daff7dd-6122-3cb9-ad16-8a3df5fa8764",
        "contentType": "STORY",
        "title": "Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug",
        "description": "",
        "summary": "The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.",
        "pubDate": "2025-12-23T01:09:58Z",
        "displayTime": "2025-12-23T01:09:58Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8daff7dd-6122-3cb9-ad16-8a3df5fa8764/novo-nordisk-jumps-as-fda-oks.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YiKgI2utbRoeUo10UfMm9A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wGfYYRb5xDf1JRG.uzPz.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-stock-jumps-fda-oks-wegovy-pill-first-oral-glp-1-weight-loss-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T00:29:18+00:00",
    "headline": "Why Abivax Stock Was on Fire Today",
    "summary": "Investors were excited about the possibility of a buyout with a high price tag.",
    "url": "https://www.fool.com/investing/2025/12/22/why-abivax-stock-was-on-fire-today/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "332eba4d-b714-3d48-8a2a-a0a1ee18efe1",
      "content": {
        "id": "332eba4d-b714-3d48-8a2a-a0a1ee18efe1",
        "contentType": "STORY",
        "title": "Why Abivax Stock Was on Fire Today",
        "description": "",
        "summary": "Investors were excited about the possibility of a buyout with a high price tag.",
        "pubDate": "2025-12-23T00:29:18Z",
        "displayTime": "2025-12-23T00:29:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45",
          "originalWidth": 1400,
          "originalHeight": 935,
          "caption": "Person in white lab coat inspecting pharmacy shelves.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RpHO07p4Wy7kIzvpj1E8tA--~B/aD05MzU7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45.cf.webp",
              "width": 1400,
              "height": 935,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4orWm0qM6SFVqYvBE_TnGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/22/why-abivax-stock-was-on-fire-today/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-abivax-stock-fire-today-002918711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T05:16:14+00:00",
    "headline": "Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "690e6da6-9d98-3549-9fc1-298cfd6447f3",
      "content": {
        "id": "690e6da6-9d98-3549-9fc1-298cfd6447f3",
        "contentType": "STORY",
        "title": "Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […]",
        "pubDate": "2025-12-23T05:16:14Z",
        "displayTime": "2025-12-23T05:16:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "SLG"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "TSM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:24:00+00:00",
    "headline": "GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly",
    "summary": "The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t",
    "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "cca6e038-8238-32de-b5f8-b7c98131cac4",
      "content": {
        "id": "cca6e038-8238-32de-b5f8-b7c98131cac4",
        "contentType": "STORY",
        "title": "GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly",
        "description": "",
        "summary": "The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t",
        "pubDate": "2025-12-23T09:24:00Z",
        "displayTime": "2025-12-23T09:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "GLP-1 Agonists Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T_Uf2N6aoGqSZF7HD6kbng--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xXR2G_pm2FrjJy91u1wQGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:10:24+00:00",
    "headline": "Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill",
    "summary": "Investing.com -- Shares in Novo Nordisk jumped Tuesday after the company won U.S. approval for its GLP-1 weight-loss pill, marking the first time such a treatment has been cleared in oral form.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "a9b49c38-57ca-3601-8229-a731d321b787",
      "content": {
        "id": "a9b49c38-57ca-3601-8229-a731d321b787",
        "contentType": "STORY",
        "title": "Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill",
        "description": "",
        "summary": "Investing.com -- Shares in Novo Nordisk jumped Tuesday after the company won U.S. approval for its GLP-1 weight-loss pill, marking the first time such a treatment has been cleared in oral form.",
        "pubDate": "2025-12-23T09:10:24Z",
        "displayTime": "2025-12-23T09:10:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:00:04+00:00",
    "headline": "Trending tickers: Tesla, Novo Nordisk, Starfighters Space, and Pets at Home",
    "summary": "The latest investor updates on stocks that are trending on Tuesday",
    "url": "https://uk.finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "28b542c5-f7a6-4533-b9dd-885ea875cdee",
      "content": {
        "id": "28b542c5-f7a6-4533-b9dd-885ea875cdee",
        "contentType": "STORY",
        "title": "Trending tickers: Tesla, Novo Nordisk, Starfighters Space, and Pets at Home",
        "description": "",
        "summary": "The latest investor updates on stocks that are trending on Tuesday",
        "pubDate": "2025-12-23T09:00:04Z",
        "displayTime": "2025-12-23T09:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a",
          "originalWidth": 5720,
          "originalHeight": 3908,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4cS7rakNv0m_GxYKfwR6vg--~B/aD0zOTA4O3c9NTcyMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a.cf.webp",
              "width": 5720,
              "height": 3908,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZKYm7xZkCB6MWDW0xayMgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "BYDDF"
            },
            {
              "symbol": "BYDDY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "PAHGF"
            },
            {
              "symbol": "PHGPY"
            },
            {
              "symbol": "JSAIY"
            },
            {
              "symbol": "JSNSF"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "002594.SZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SBRY.L"
            },
            {
              "symbol": "LMT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T10:05:00+00:00",
    "headline": "Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy",
    "summary": "Novo Nordisk  shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill.  The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and  Eli Lilly’s  Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution.  Shares in Novo Nordisk rose as much as 8% in European morning trading Tuesday.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-jump-after-fda-approves-pill-version-of-wegovy-0c759799?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "bf8133a2-d1be-3610-a031-323528bc57c1",
      "content": {
        "id": "bf8133a2-d1be-3610-a031-323528bc57c1",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy",
        "description": "",
        "summary": "Novo Nordisk  shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill.  The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and  Eli Lilly’s  Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution.  Shares in Novo Nordisk rose as much as 8% in European morning trading Tuesday.",
        "pubDate": "2025-12-23T10:05:00Z",
        "displayTime": "2025-12-23T10:05:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/bf8133a2-d1be-3610-a031-323528bc57c1/novo-nordisk-shares-jump.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e0BgLnvPpwyh7Pjsw4EP6Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jTiPV.FuS9unTJ78fAHifQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-jump-after-fda-approves-pill-version-of-wegovy-0c759799?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:43:00+00:00",
    "headline": "Pill Version of Wegovy Is Approved for Use in the U.S.",
    "summary": "Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.",
    "url": "https://www.wsj.com/health/pharma/pill-version-of-wegovy-is-approved-for-use-in-the-u-s-6d6a6f2d?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "4c8488a3-403f-3c55-9b54-702e7df9bb01",
      "content": {
        "id": "4c8488a3-403f-3c55-9b54-702e7df9bb01",
        "contentType": "STORY",
        "title": "Pill Version of Wegovy Is Approved for Use in the U.S.",
        "description": "",
        "summary": "Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.",
        "pubDate": "2025-12-23T09:43:00Z",
        "displayTime": "2025-12-23T09:43:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4c8488a3-403f-3c55-9b54-702e7df9bb01/pill-version-of-wegovy-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1SHu8WUYGwFvreI1qVJ2A--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RApsOqmUMyIICUUqEeo1RQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/pill-version-of-wegovy-is-approved-for-use-in-the-u-s-6d6a6f2d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:37:23+00:00",
    "headline": "Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity",
    "summary": "Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.",
    "url": "https://www.pharmaceutical-technology.com/news/novo-beats-lilly-to-first-fda-approved-glp-1ra-pill-for-obesity/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "53729f95-fb09-30bb-a0ee-966d6dd3414c",
      "content": {
        "id": "53729f95-fb09-30bb-a0ee-966d6dd3414c",
        "contentType": "STORY",
        "title": "Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity",
        "description": "",
        "summary": "Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.",
        "pubDate": "2025-12-23T11:37:23Z",
        "displayTime": "2025-12-23T11:37:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RseODmWOW4IbPIp37PX_zA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UCyGFLu6xa6Cw8DriKhedg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/novo-beats-lilly-to-first-fda-approved-glp-1ra-pill-for-obesity/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-beats-lilly-first-fda-113723797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:28:23+00:00",
    "headline": "Novo Nordisk Jumps 7% After FDA Approves First Ever GLP-1 Pill",
    "summary": "Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "9ac2e64f-67dc-3b4b-8832-c32f7e734a40",
      "content": {
        "id": "9ac2e64f-67dc-3b4b-8832-c32f7e734a40",
        "contentType": "STORY",
        "title": "Novo Nordisk Jumps 7% After FDA Approves First Ever GLP-1 Pill",
        "description": "",
        "summary": "Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.",
        "pubDate": "2025-12-23T11:28:23Z",
        "displayTime": "2025-12-23T11:28:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T10:48:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, Zim, and More",
    "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
    "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
      "content": {
        "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, Zim, and More",
        "description": "",
        "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
        "pubDate": "2025-12-23T10:48:00Z",
        "displayTime": "2025-12-23T10:48:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dcb96691-f52a-395f-be81-e7695e1ffdcb/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDwEUpGkdEDr789NVbU8CA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tKnpo.hIxRqi7QH6r_KIGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HII"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "ZIM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T12:55:34+00:00",
    "headline": "Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers",
    "summary": "Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.",
    "url": "https://www.just-drinks.com/news/arrival-of-glp-1-weight-loss-pill-creates-new-headache-for-food-drink-makers/",
    "source": "Just Drinks",
    "provider": "yfinance",
    "raw": {
      "id": "d99b4f0f-f8ed-33f0-8908-624bc522b887",
      "content": {
        "id": "d99b4f0f-f8ed-33f0-8908-624bc522b887",
        "contentType": "STORY",
        "title": "Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers",
        "description": "",
        "summary": "Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.",
        "pubDate": "2025-12-23T12:55:34Z",
        "displayTime": "2025-12-23T12:55:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/just_drinks_442/60ca871010474f039d83125653f76cf4",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "https://www.shutterstock.com/image-photo/bottle-weight-loss-pills-scales-measuring-2468075461?trackingId=41f66115-073e-4d90-b8f0-56c37ccf85a6",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4yjt6bpcK6u7dKjA0EB2MQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/just_drinks_442/60ca871010474f039d83125653f76cf4.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bun3eqGNGLfy_4AqbCcyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/just_drinks_442/60ca871010474f039d83125653f76cf4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Just Drinks",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.just-drinks.com/news/arrival-of-glp-1-weight-loss-pill-creates-new-headache-for-food-drink-makers/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arrival-glp-1-weight-loss-125534704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:45:00+00:00",
    "headline": "Novo Nordisk Wegovy Weight-Loss Pill Approved in U.S. Eli Lilly Stock Falls.",
    "summary": "Eli Lilly  stock fell on Tuesday after  Novo Nordisk  its rival in diabetes and weight-loss drugs, secured regulatory approval for a weight-loss pill in the U.S.  Novo shares were rallying after it announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.  “The pill is here,” Novo CEO Mike Doustdar said in a statement.",
    "url": "https://www.barrons.com/articles/novo-nordisk-wegovy-pill-eli-lilly-stock-383b56f4?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
      "content": {
        "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
        "contentType": "STORY",
        "title": "Novo Nordisk Wegovy Weight-Loss Pill Approved in U.S. Eli Lilly Stock Falls.",
        "description": "",
        "summary": "Eli Lilly  stock fell on Tuesday after  Novo Nordisk  its rival in diabetes and weight-loss drugs, secured regulatory approval for a weight-loss pill in the U.S.  Novo shares were rallying after it announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.  “The pill is here,” Novo CEO Mike Doustdar said in a statement.",
        "pubDate": "2025-12-23T11:45:00Z",
        "displayTime": "2025-12-23T11:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f/novo-nordisk-wegovy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wEBOOCiLOsdrdziAJMy3Lg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_t_96VCjJOiStdFYd0iHSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-wegovy-pill-eli-lilly-stock-383b56f4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T14:09:36+00:00",
    "headline": "Stock futures, gold record high, FDA approves GLP-1 pill: 3 Things",
    "summary": "US stock futures (ES=F, NQ=F, YM=F) are moving lower after the S&P 500 (^GSPC) closed higher on Monday, notching its third straight day of gains. Gold prices (GC=F) continue to climb to record highs this week, now ascending above $4,500 per ounce. The US Food and Drug Administration (FDA) has approved the first GLP-1 weight-loss pill from Novo Nordisk (NVO), with Eli Lilly (LLY) expected to soon reveal its own oral obesity drug. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/stock-futures-gold-record-high-140936955.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "a9b86f0a-8e1b-397a-bc1f-a2a0ad7be46c",
      "content": {
        "id": "a9b86f0a-8e1b-397a-bc1f-a2a0ad7be46c",
        "contentType": "VIDEO",
        "title": "Stock futures, gold record high, FDA approves GLP-1 pill: 3 Things",
        "description": "<p>US stock futures (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/ES%3DF\">ES=F</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/NQ%3DF\">NQ=F</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/YM%3DF\">YM=F</a>) are moving lower after the S&P 500 (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/%5EGSPC\">^GSPC</a>) closed higher on Monday, notching its third straight day of gains.</p>\n<p>Gold prices (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/GC=F\">GC=F</a>) continue to <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/news/gold-silver-hit-record-highs-as-precious-metals-pace-toward-best-year-since-1979-175056057.html\">climb to record highs </a>this week, now ascending above $4,500 per ounce.</p>\n<p>The US Food and Drug Administration (FDA) has approved the first GLP-1 weight-loss pill from Novo Nordisk (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>), with Eli Lilly (<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) expected to soon reveal its own oral obesity drug.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:9;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "US stock futures (ES=F, NQ=F, YM=F) are moving lower after the S&P 500 (^GSPC) closed higher on Monday, notching its third straight day of gains. Gold prices (GC=F) continue to climb to record highs this week, now ascending above $4,500 per ounce. The US Food and Drug Administration (FDA) has approved the first GLP-1 weight-loss pill from Novo Nordisk (NVO), with Eli Lilly (LLY) expected to soon reveal its own oral obesity drug. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2025-12-23T14:09:36Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/cb523d10-e008-11f0-bf7c-cadcd957afd5",
          "originalWidth": 5095,
          "originalHeight": 2870,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wRkZ9p7EKY_13XyasjeCEg--~B/aD0yODcwO3c9NTA5NTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/cb523d10-e008-11f0-bf7c-cadcd957afd5.cf.webp",
              "width": 5095,
              "height": 2870,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KZVNDBZf2PXDqZjI_HKDFA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/cb523d10-e008-11f0-bf7c-cadcd957afd5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/stock-futures-gold-record-high-140936955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/stock-futures-gold-record-high-140936955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "GC=F"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T14:39:05+00:00",
    "headline": "Novo's GLP-1 pill gets approved, Trump Media stock pulls back",
    "summary": "Yahoo Finance Executive Editor Brian Sozzi tracks some of Tuesday's trending tickers, including Novo Nordisk (NVO), Eli Lilly (LLY), D-Wave Quantum (QBTS), and Trump Media & Technology Group (DJT, DJTWW). To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/novos-glp-1-pill-gets-143905316.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "2e31d6b4-68b5-373b-8094-280dbed13228",
      "content": {
        "id": "2e31d6b4-68b5-373b-8094-280dbed13228",
        "contentType": "VIDEO",
        "title": "Novo's GLP-1 pill gets approved, Trump Media stock pulls back",
        "description": "<p>Yahoo Finance Executive Editor <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/brian-sozzi/\">Brian Sozzi</a> tracks some of Tuesday's trending tickers, including Novo Nordisk (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>), Eli Lilly (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>), D-Wave Quantum (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/QBTS\">QBTS</a>), and Trump Media & Technology Group (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/DJT\">DJT</a>, <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/DJTWW\">DJTWW</a>).</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "Yahoo Finance Executive Editor Brian Sozzi tracks some of Tuesday's trending tickers, including Novo Nordisk (NVO), Eli Lilly (LLY), D-Wave Quantum (QBTS), and Trump Media & Technology Group (DJT, DJTWW). To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2025-12-23T14:39:05Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/08562ca0-e00c-11f0-bb70-58eaa6383d69",
          "originalWidth": 3258,
          "originalHeight": 1835,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ki9pCX4Xb3TDsrVjfvOssA--~B/aD0xODM1O3c9MzI1ODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/08562ca0-e00c-11f0-bb70-58eaa6383d69.cf.webp",
              "width": 3258,
              "height": 1835,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yFKfcqHHI8MxiWAMoiA0Kw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/08562ca0-e00c-11f0-bb70-58eaa6383d69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novos-glp-1-pill-gets-143905316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novos-glp-1-pill-gets-143905316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "DJT"
            },
            {
              "symbol": "QBTS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T13:48:00+00:00",
    "headline": "5 Big Drug Stocks That May Continue to Outperform in 2026",
    "summary": "Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.",
    "url": "https://finance.yahoo.com/news/5-big-drug-stocks-may-134800671.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "365f8e8a-12dd-3afc-b85f-9a89dded47c3",
      "content": {
        "id": "365f8e8a-12dd-3afc-b85f-9a89dded47c3",
        "contentType": "STORY",
        "title": "5 Big Drug Stocks That May Continue to Outperform in 2026",
        "description": "",
        "summary": "Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.",
        "pubDate": "2025-12-23T13:48:00Z",
        "displayTime": "2025-12-23T13:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbSgl25Zi2GiiDMk0hXrSg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NAknAcj0fz57CxpyeoYG3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-big-drug-stocks-may-134800671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-big-drug-stocks-may-134800671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T16:27:09+00:00",
    "headline": "Novo Nordisk Loses Weight-Loss Lead as Lilly Gains Ground",
    "summary": "Competition from Eli Lilly, copycat drugs, and pricing pressure is reshaping Novo's outlook despite an upcoming oral Wegovy launch.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-loses-weight-loss-162709325.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "99fb90d1-ca39-33b5-a3b1-5a6a710c3bb5",
      "content": {
        "id": "99fb90d1-ca39-33b5-a3b1-5a6a710c3bb5",
        "contentType": "STORY",
        "title": "Novo Nordisk Loses Weight-Loss Lead as Lilly Gains Ground",
        "description": "",
        "summary": "Competition from Eli Lilly, copycat drugs, and pricing pressure is reshaping Novo's outlook despite an upcoming oral Wegovy launch.",
        "pubDate": "2025-12-23T16:27:09Z",
        "displayTime": "2025-12-23T16:27:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-loses-weight-loss-162709325.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-loses-weight-loss-162709325.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:36:00+00:00",
    "headline": "Novo Nordisk Stock Soars After Weight-Loss Pill Approved in U.S. What It Means for Eli Lilly.",
    "summary": "Eli Lilly  stock was on the outside looking in on Tuesday as shares of  Novo Nordisk  its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S.  Novo stock was up 9.6% at $52.73, its biggest gain since Aug. 8, 2023, after it announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-weight-loss-pill-eli-lilly-wegovy-383b56f4?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
      "content": {
        "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Soars After Weight-Loss Pill Approved in U.S. What It Means for Eli Lilly.",
        "description": "",
        "summary": "Eli Lilly  stock was on the outside looking in on Tuesday as shares of  Novo Nordisk  its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S.  Novo stock was up 9.6% at $52.73, its biggest gain since Aug. 8, 2023, after it announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.",
        "pubDate": "2025-12-23T15:36:00Z",
        "displayTime": "2025-12-23T15:36:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f/novo-nordisk-stock-soars.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wEBOOCiLOsdrdziAJMy3Lg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_t_96VCjJOiStdFYd0iHSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-weight-loss-pill-eli-lilly-wegovy-383b56f4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:29:00+00:00",
    "headline": "Why Eli Lilly Shares Are Down On Tuesday",
    "summary": "Eli Lilly Faces Pressure as Novo's Daily Pill Hits the Market;'",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-shares-down-152900646.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "7edd4556-2456-31da-bfbe-09e3723ed143",
      "content": {
        "id": "7edd4556-2456-31da-bfbe-09e3723ed143",
        "contentType": "STORY",
        "title": "Why Eli Lilly Shares Are Down On Tuesday",
        "description": "",
        "summary": "Eli Lilly Faces Pressure as Novo's Daily Pill Hits the Market;'",
        "pubDate": "2025-12-23T15:29:00Z",
        "displayTime": "2025-12-23T15:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-shares-down-152900646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-shares-down-152900646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T14:50:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, ServiceNow, Micron, DJT, Zim, and More",
    "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
    "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
      "content": {
        "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, ServiceNow, Micron, DJT, Zim, and More",
        "description": "",
        "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
        "pubDate": "2025-12-23T14:50:00Z",
        "displayTime": "2025-12-23T14:50:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dcb96691-f52a-395f-be81-e7695e1ffdcb/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDwEUpGkdEDr789NVbU8CA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tKnpo.hIxRqi7QH6r_KIGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "HII"
            },
            {
              "symbol": "ZIM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:16:00+00:00",
    "headline": "Novo Nordisk’s weight loss pill approved by FDA",
    "summary": "The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.",
    "url": "https://www.biopharmadive.com/news/novo-nordisk-oral-wegovy-fda-approve-glp-1/808578/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "91a9da15-07b2-3438-9714-75466c94c141",
      "content": {
        "id": "91a9da15-07b2-3438-9714-75466c94c141",
        "contentType": "STORY",
        "title": "Novo Nordisk’s weight loss pill approved by FDA",
        "description": "",
        "summary": "The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.",
        "pubDate": "2025-12-23T11:16:00Z",
        "displayTime": "2025-12-23T11:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/85c95ba92bb4851bc2779d366d710756",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A Novo Nordisk sign is seen on the side of a building in California in March 2020.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rxirqdG.5ekVZWwapDcbEA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/85c95ba92bb4851bc2779d366d710756.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lVxkCXxtrB2Gs4bHJxt8Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/85c95ba92bb4851bc2779d366d710756.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-nordisk-oral-wegovy-fda-approve-glp-1/808578/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-pill-111600355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:46:00+00:00",
    "headline": "Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up",
    "summary": "NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-wins-fda-nod-154600889.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f135ee64-c566-3840-bb39-cf7e105b762a",
      "content": {
        "id": "f135ee64-c566-3840-bb39-cf7e105b762a",
        "contentType": "STORY",
        "title": "Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up",
        "description": "",
        "summary": "NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.",
        "pubDate": "2025-12-23T15:46:00Z",
        "displayTime": "2025-12-23T15:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-wins-fda-nod-154600889.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-wins-fda-nod-154600889.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:35:00+00:00",
    "headline": "CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies",
    "summary": "CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.",
    "url": "https://finance.yahoo.com/news/crsp-stock-rises-encouraging-early-153500692.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "197af53e-b7bc-3972-8505-f401d36eacc1",
      "content": {
        "id": "197af53e-b7bc-3972-8505-f401d36eacc1",
        "contentType": "STORY",
        "title": "CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies",
        "description": "",
        "summary": "CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.",
        "pubDate": "2025-12-23T15:35:00Z",
        "displayTime": "2025-12-23T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-rises-encouraging-early-153500692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-rises-encouraging-early-153500692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:27:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso",
    "summary": "Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-152700738.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "43e3a540-b1a7-3fda-a28e-b9a914a23e48",
      "content": {
        "id": "43e3a540-b1a7-3fda-a28e-b9a914a23e48",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso",
        "description": "",
        "summary": "Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.",
        "pubDate": "2025-12-23T15:27:00Z",
        "displayTime": "2025-12-23T15:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-152700738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-152700738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RYDAF"
            },
            {
              "symbol": "IBN"
            },
            {
              "symbol": "SHEL"
            },
            {
              "symbol": "FEIM"
            },
            {
              "symbol": "VASO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T15:14:00+00:00",
    "headline": "Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?",
    "summary": "NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-vs-amgen-healthcare-151400304.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "835f1203-774b-3bde-9adb-960484c0e4bf",
      "content": {
        "id": "835f1203-774b-3bde-9adb-960484c0e4bf",
        "contentType": "STORY",
        "title": "Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?",
        "description": "",
        "summary": "NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.",
        "pubDate": "2025-12-23T15:14:00Z",
        "displayTime": "2025-12-23T15:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-vs-amgen-healthcare-151400304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-vs-amgen-healthcare-151400304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T04:04:29+00:00",
    "headline": "3 Reasons Investors Love Eli Lilly (LLY)",
    "summary": "Eli Lilly currently trades at $1,061 and has been a dream stock for shareholders. It’s returned 541% since December 2020, blowing past the S&P 500’s 85.2% gain. The company has also beaten the index over the past six months as its stock price is up 37.7% thanks to its solid quarterly results.",
    "url": "https://finance.yahoo.com/news/3-reasons-investors-love-eli-040429547.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "c9baa785-8f5d-3576-9987-411320e73180",
      "content": {
        "id": "c9baa785-8f5d-3576-9987-411320e73180",
        "contentType": "STORY",
        "title": "3 Reasons Investors Love Eli Lilly (LLY)",
        "description": "",
        "summary": "Eli Lilly currently trades at $1,061 and has been a dream stock for shareholders. It’s returned 541% since December 2020, blowing past the S&P 500’s 85.2% gain. The company has also beaten the index over the past six months as its stock price is up 37.7% thanks to its solid quarterly results.",
        "pubDate": "2025-12-23T04:04:29Z",
        "displayTime": "2025-12-23T04:04:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-investors-love-eli-040429547.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-investors-love-eli-040429547.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T17:17:37+00:00",
    "headline": "Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers",
    "summary": "Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.",
    "url": "https://www.just-food.com/news/arrival-of-glp-1-weight-loss-pill-creates-new-headache-for-food-drink-makers/",
    "source": "Just Food",
    "provider": "yfinance",
    "raw": {
      "id": "c3abcaa8-322a-35a3-b35f-7447c8a26595",
      "content": {
        "id": "c3abcaa8-322a-35a3-b35f-7447c8a26595",
        "contentType": "STORY",
        "title": "Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers",
        "description": "",
        "summary": "Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.",
        "pubDate": "2025-12-23T17:17:37Z",
        "displayTime": "2025-12-23T17:17:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/just_food_692/388af73883dcd8d5c04d65ed39bd0895",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Wegovy weight-loss drug pens on table",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kr.md.7DhmUD2kO7g4oU8w--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/just_food_692/388af73883dcd8d5c04d65ed39bd0895.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zb.kHKjwskGrDUe.WX2T5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/just_food_692/388af73883dcd8d5c04d65ed39bd0895.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Just Food",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.just-food.com/news/arrival-of-glp-1-weight-loss-pill-creates-new-headache-for-food-drink-makers/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arrival-glp-1-weight-loss-125534312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T17:10:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More",
    "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
    "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
      "content": {
        "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More",
        "description": "",
        "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
        "pubDate": "2025-12-23T17:10:00Z",
        "displayTime": "2025-12-23T17:10:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dcb96691-f52a-395f-be81-e7695e1ffdcb/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDwEUpGkdEDr789NVbU8CA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tKnpo.hIxRqi7QH6r_KIGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NOW"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "FCX"
            },
            {
              "symbol": "ZIM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T16:46:00+00:00",
    "headline": "Wegovy Pill Approval Sends Novo Nordisk Stock Soaring. What It Means for Eli Lilly.",
    "summary": "Eli Lilly  stock was on the outside looking in on Tuesday as shares of  Novo Nordisk  its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S.  Novo’s American depositary receipts were up 8.7% at $52.28, their biggest gain since Aug. 8, 2023, after the company announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.  Novo said it expects to launch the Wegovy pill in the U.S. in early January.",
    "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-weight-loss-pill-eli-lilly-wegovy-383b56f4?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
      "content": {
        "id": "8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f",
        "contentType": "STORY",
        "title": "Wegovy Pill Approval Sends Novo Nordisk Stock Soaring. What It Means for Eli Lilly.",
        "description": "",
        "summary": "Eli Lilly  stock was on the outside looking in on Tuesday as shares of  Novo Nordisk  its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S.  Novo’s American depositary receipts were up 8.7% at $52.28, their biggest gain since Aug. 8, 2023, after the company announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.  Novo said it expects to launch the Wegovy pill in the U.S. in early January.",
        "pubDate": "2025-12-23T16:46:00Z",
        "displayTime": "2025-12-23T16:46:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e089ff3-4d34-33d3-8a84-c28f9d8f4b0f/wegovy-pill-approval-sends.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wEBOOCiLOsdrdziAJMy3Lg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_t_96VCjJOiStdFYd0iHSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a5a25d6b6d56c0ab6d0cfd195ae6638b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-stock-price-weight-loss-pill-eli-lilly-wegovy-383b56f4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T18:23:29+00:00",
    "headline": "Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?",
    "summary": "Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — semaglutide — as the injectable Wegovy and Ozempic, but in a higher 25 mg dose to achieve comparable efficacy despite lower absorption because it is taken orally. ... Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?",
    "url": "https://247wallst.com/investing/2025/12/23/novo-nordisk-strikes-first-with-oral-wegovy-but-can-it-outrun-lillys-looming-pill/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3f7dc4c9-17d6-32d2-b6b7-ec7846674e6e",
      "content": {
        "id": "3f7dc4c9-17d6-32d2-b6b7-ec7846674e6e",
        "contentType": "STORY",
        "title": "Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?",
        "description": "",
        "summary": "Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — semaglutide — as the injectable Wegovy and Ozempic, but in a higher 25 mg dose to achieve comparable efficacy despite lower absorption because it is taken orally. ... Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?",
        "pubDate": "2025-12-23T18:23:29Z",
        "displayTime": "2025-12-23T18:23:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/aed468ddfc8da084687bcc8b31ff2cdf",
          "originalWidth": 1500,
          "originalHeight": 998,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GKRyMH99EOXZvyKWtwh3Ew--~B/aD05OTg7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/aed468ddfc8da084687bcc8b31ff2cdf.cf.webp",
              "width": 1500,
              "height": 998,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dqA3RD3h6WZ.bNHuf.3XYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/aed468ddfc8da084687bcc8b31ff2cdf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/23/novo-nordisk-strikes-first-with-oral-wegovy-but-can-it-outrun-lillys-looming-pill/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-strikes-first-oral-182329509.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T22:02:18+00:00",
    "headline": "Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill",
    "summary": "On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.",
    "url": "https://www.fool.com/coverage/stock-market-today/2025/12/23/stock-market-today-dec-23-novo-nordisk-surges-after-fda-approves-oral-wegovy-weight-loss-pill/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "17e4c213-4327-3bbd-a336-9b0c2e633e01",
      "content": {
        "id": "17e4c213-4327-3bbd-a336-9b0c2e633e01",
        "contentType": "STORY",
        "title": "Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill",
        "description": "",
        "summary": "On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.",
        "pubDate": "2025-12-23T22:02:18Z",
        "displayTime": "2025-12-23T22:02:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/083eb51f57dad5037b90277a20d85750",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QOjcb6MMoZrFQ4Z0yWa1Tw--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/083eb51f57dad5037b90277a20d85750.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AHC2DkVOqvXAk4Lo5ZPz8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/083eb51f57dad5037b90277a20d85750.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2025/12/23/stock-market-today-dec-23-novo-nordisk-surges-after-fda-approves-oral-wegovy-weight-loss-pill/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-dec-23-220218802.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T21:15:00+00:00",
    "headline": "These Stocks Moved the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More",
    "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
    "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
      "content": {
        "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
        "contentType": "STORY",
        "title": "These Stocks Moved the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More",
        "description": "",
        "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
        "pubDate": "2025-12-23T21:15:00Z",
        "displayTime": "2025-12-23T21:15:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dcb96691-f52a-395f-be81-e7695e1ffdcb/these-stocks-moved-the-most.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDwEUpGkdEDr789NVbU8CA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tKnpo.hIxRqi7QH6r_KIGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "NOW"
            },
            {
              "symbol": "FCX"
            },
            {
              "symbol": "ZIM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]